News for 'pharmaceutical'

Governments should not become trigger-happy about lockdowns

Governments should not become trigger-happy about lockdowns

Rediff.com7 Jan 2022

Sure we understand that isolating affected communities is part of the pandemic protocol, but we don't wish our life and freedom to be tossed aside at the slightest excuse, states Shyam G Menon.

Draft rules propose doctors disclose income from pharma companies

Draft rules propose doctors disclose income from pharma companies

Rediff.com8 Jun 2022

Defining "modern medicine" for the first time, the National Medical Commission (NMC), in its code of conduct, has introduced a major change, proposing the use of "Med Dr" as a prefix for those registered under the NMC Act, 2019, as practitioners of modern medicine.

India's economy could prove to be 'most resilient' in subregion over long term: UN

India's economy could prove to be 'most resilient' in subregion over long term: UN

Rediff.com29 Dec 2020

India's economy could prove to be the "most resilient" in the subregion of South and South-West Asia over the long term, according to a report by the UN, which says a positive but lower economic growth post COVID-19 pandemic and the country's large market will continue to attract investments. The report titled 'Foreign Direct Investment Trends And Outlook In Asia And The Pacific 2020/2021', and compiled by United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), stated that inward FDI flows to South and South-West Asia slightly decreased by 2 per cent in 2019, from $67 billion in 2018 to $66 billion in 2019. The growth, however, was mainly driven by India, which accounted for 77 per cent of the total inflows to the subregion and received $51 billion in 2019, up 20 per cent from the previous year.

Bharat Biotech's Covaxin vaccine cleared by special panel

Bharat Biotech's Covaxin vaccine cleared by special panel

Rediff.com2 Jan 2021

Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.

Ahmed Patel's son-in-law, Dino Morea's assets seized in PMLA case

Ahmed Patel's son-in-law, Dino Morea's assets seized in PMLA case

Rediff.com2 Jul 2021

The Enforcement Directorate has alleged that this is a bigger bank scam in volume than that of the Punjab National Bank fraud by fugitive diamantaires Nirav Modi and Mehul Choksi, as it involves fraud to the tune of about Rs 16,000 crore.

Coronavirus: No shortage of medicines, says govt

Coronavirus: No shortage of medicines, says govt

Rediff.com5 Mar 2020

'There is no shortage of any APIs (active pharmaceutical ingredients) in the country'

Netherlands is now India's 5th-largest export destination

Netherlands is now India's 5th-largest export destination

Rediff.com23 May 2022

The Netherlands has emerged as India's fifth-largest export destination in 2021-22 (FY22), jumping from its 10th position a year ago. Exports to the fifth-largest economy in the European Union (EU) bolted 94 per cent to $12.5 billion in the financial year ended March 31. In FY22, the Netherlands surpassed Hong Kong, Singapore, the UK, Germany, and Nepal to become India's largest export destination in the EU. Germany, which was earlier India's top European export destination (eighth position), has now dropped two ranks to 10th place.

Sputnik V jabs to be available in 9 more cities across India

Sputnik V jabs to be available in 9 more cities across India

Rediff.com17 Jun 2021

Russian COVID-19 vaccine Sputnik V vaccine will be available in nine more cities across India, including Bengaluru, Mumbai, Chennai, Visakhapatnam, Baddi, Kolhapur and Miryalaguda, informed the official twitter handle of Sputnik V.

India's pharma cos hit by 'China-made disruptions'

India's pharma cos hit by 'China-made disruptions'

Rediff.com31 Mar 2022

With intermittent disruptions in the supply chain of raw materials from China, the Indian pharma industry has braced itself with bigger inventory. Even smaller drug makers are now carrying a month of buffer stock of key raw materials, said industry insiders. The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players. Shipments are critical for the Indian drug industry, which imports 70 per cent of its raw material from China.

Share of family-owned firms in total market capitalisation rises to 64.5%

Share of family-owned firms in total market capitalisation rises to 64.5%

Rediff.com4 Jan 2021

The growth was led by family-owned companies and business groups with presence in pharmaceuticals, information technology services, and consumer products.

Senior bureaucrat P D Vaghela appointed TRAI chairman

Senior bureaucrat P D Vaghela appointed TRAI chairman

Rediff.com28 Sep 2020

He has been appointed as the TRAI chief for three years or till he attains the age of 65.

Brazil scraps Covaxin's EUA application

Brazil scraps Covaxin's EUA application

Rediff.com27 Jul 2021

The Brazilian health regulator's decision comes after the vaccine maker informed the South American country about the termination of its pact with its partners in that country.

ASK AJIT: 'Which shares to buy short term and long term?'

ASK AJIT: 'Which shares to buy short term and long term?'

Rediff.com17 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.

Sputnik V vaccine may be added to India's Covid armoury soon

Sputnik V vaccine may be added to India's Covid armoury soon

Rediff.com30 Mar 2021

'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).

Coronavirus impact: Govt restricts exports of 13 APIs, formulations

Coronavirus impact: Govt restricts exports of 13 APIs, formulations

Rediff.com4 Mar 2020

Exports of 13 APIs - including paracetamol, tinidazole, metronidazole, vitamin B1, vitamin B6, vitamin B12, acyclovir, progesterone - along with formulations made from these APIs, would be restricted.

Rakesh Jhunjhunwala rejigs portfolio in Q2; ups stake in Lupin, Tata Motors

Rakesh Jhunjhunwala rejigs portfolio in Q2; ups stake in Lupin, Tata Motors

Rediff.com30 Oct 2020

The duo bought additional shares in pharmaceutical companies Lupin and Jubilant Life Sciences, along with Agro Tech Foods and NCC during Q2FY21

Why Chinese imports are likely to continue

Why Chinese imports are likely to continue

Rediff.com26 Jun 2020

Indian auto and pharma industries import several critical components and raw materials from China.

Dom's Take: Atmanirbhar or Nirbhar Vaccine?

Dom's Take: Atmanirbhar or Nirbhar Vaccine?

Rediff.com25 Nov 2020

Dominic Xavier wonders if the PM will opt for the Indian-made COVID-19 vaccine for the sake of Atmanirbhar Bharat.

Trade margins capped at 70% for oximeters, BP meters, other medical devices

Trade margins capped at 70% for oximeters, BP meters, other medical devices

Rediff.com14 Jul 2021

The medical devices, which have been in high demand during the Covid-19 pandemic, will now see a drop in prices, as the earlier margins were up to 709 per cent for some of these products.

Dom's Take: The race for COVID-19 vaccine

Dom's Take: The race for COVID-19 vaccine

Rediff.com17 Nov 2020

Dominic Xavier wonders when human beings can access the vaccine and terminate the mayhem caused by the coronavirus.

Bharat Biotech to rectify issues with Covaxin raised by WHO

Bharat Biotech to rectify issues with Covaxin raised by WHO

Rediff.com5 Apr 2022

According to sources close to ANI, "Bharat Biotech has informed Union health ministry that it will rectify the issues pointed out by WHO in 15 to 20 days." "World Health Organisation (WHO)'s suspension is not related to safety or efficacy issues but limited only to supply for United Nations agencies."

FM to boost Budget spending to support economic growth

FM to boost Budget spending to support economic growth

Rediff.com31 Jan 2022

Finance Minister Nirmala Sitharaman is likely to strike a fine balance between being fiscally prudent and growth supportive when she presents her fourth straight budget on Tuesday, which is expected to have plans to boost spending to revive investment and create jobs. The Budget for the fiscal year starting April 1, 2022 is likely to raise spending on infrastructure to set the economy on a firmer footing. The stage for the Budget presentation was set by the Economic Survey stating that the government has the fiscal space to do more to support the economy that is forecast to grow at a healthy 8-8.5 per cent growth in the 2022-23 fiscal.

Omicron may put export growth in slow lane

Omicron may put export growth in slow lane

Rediff.com10 Jan 2022

Uncertainty looms over India's export outlook, with the new Covid-19 variant Omicron spreading rapidly across the country's key shipment destinations. With the US and parts of Europe witnessing more than 100,000 Covid-19 cases a day, exporters expect some disruption. However, there may not be an immediate decline in exports from India because the order books remain strong at least for the next few weeks, they said.

Gujarat pharma hub hit by near-zero exports

Gujarat pharma hub hit by near-zero exports

Rediff.com15 Apr 2020

With the government asking the companies to operate with only 50 per cent staff strength, and exports dipping to almost zero, the truck and bus drivers idling at the petrol pump say they hardly have any work now. At a petrol pump on the deserted Bavla-Changodar highway near Ahmedabad in Gujarat, several trucks and buses are neatly parked in a row.

BMC claims Mumbai received bid from Pfizer for vaccine, company denies

BMC claims Mumbai received bid from Pfizer for vaccine, company denies

Rediff.com25 May 2021

After Brihanmumbai Municipal Corporation Commissioner Iqbal Singh Chahal claimed that Mumbai has received a bid from Pfizer in response to its COVID-19 vaccine procurement tender, Pfizer issued a statement clarifying that it has made no such bid.

Remdesivir black-market thrives as Covid cases rise

Remdesivir black-market thrives as Covid cases rise

Rediff.com6 May 2021

Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das

'Famotidine may become the next HCQ for Covid-19'

'Famotidine may become the next HCQ for Covid-19'

Rediff.com10 May 2020

Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its clinical trials, it led to a drug shortage in the US. Back home, however, there has not been any surge in the demand for Famotidine yet.

World University Rankings: Non-IITs in Top 100

World University Rankings: Non-IITs in Top 100

Rediff.com11 Apr 2022

The Saveetha Institute of Medical and Technical Sciences. The Indian School of Mines, Dhanbad. Vinay Umarji explains why these two universities have made India proud.

DCGI takes BIG step for rollout of foreign vaccines in India

DCGI takes BIG step for rollout of foreign vaccines in India

Rediff.com2 Jun 2021

"It has been decided that for approval of COVID-19 vaccines in India for restricted use in emergency situation which are already approved for restricted use by US Food Drug Administration, European Medicines Agency, UK Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency Japan or which are listed in WHO Emergency Use Listing and which are well established vaccines from the stand point that millions of individuals have already been vaccinated with the said vaccines, the requirement of conducting post approval bridging clinical trials and of testing every batch of vaccine by CDL, Kasauli can be exempted, if the vaccine batch/lot has been certified and released by National Control Laboratory of country of origin," it said.

After 6 months in red, exports finally turn positive in Sep

After 6 months in red, exports finally turn positive in Sep

Rediff.com16 Oct 2020

After contracting for six straight months, India's exports rose 5.99 per cent to $27.58 billion in September on account of growth in shipments of drugs and pharmaceuticals and readymade garments, as per the government data released on Thursday. Exports stood at $26.02 billion in September 2019. The country's imports contracted 19.6 per cent to $30.31 billion in September.

PM CARES Fund corpus triples to Rs 10,990 cr in FY 2020-21

PM CARES Fund corpus triples to Rs 10,990 cr in FY 2020-21

Rediff.com7 Feb 2022

The disbursal included Rs 1,000 crore for migrant welfare and over Rs 1,392 crore for procurement of Covid vaccine doses.

Budget: Concessional rate dumped, foreign dividends now under tax ambit

Budget: Concessional rate dumped, foreign dividends now under tax ambit

Rediff.com2 Feb 2022

Concessional rate of tax on dividends received by Indian companies from foreign subsidiaries will be done away with from April 1, a change that may hamper global expansion of Indian companies and compel some firms to move their headquarters out of India to geographies such as Singapore and Dubai. At present, dividends received by Indian companies from their foreign subsidiaries are subject to a concessional tax rate of 15 per cent under Section 115BBD of the Income Tax (I-T) Act. The provisions of this section shall not apply from assessment year 2023-24 onwards, according to the Finance Bill.

US trade body hails Budget, says it's fiscally prudent

US trade body hails Budget, says it's fiscally prudent

Rediff.com2 Feb 2022

In the midst of third wave of COVID-19, Finance Minister Nirmala Sitharaman has come up with an impactful Budget which is balanced, fiscally prudent and growth-oriented, the USA India Chamber of Commerce has said. President of the Boston-based USA India Chamber of Commerce (USAIC) Karun Rishi, however, said it is a matter of concern that the budget lacks tangible measures to increase revenue generation. "Opting to keep the fiscal deficit at 6.9 per cent and increase capital expenditure by 35 per cent is a masterstroke. "The annual budget estimates the effective capital expenditure of Rs 10.68 lakh crore in 2022-23, making up about 4.1 per cent of the GDP," he said. "A phenomenal increase in the government's capital expenditure is likely to facilitate the expenditures on infrastructure and create jobs.

'Rate hike will throw lot of people out from jobs'

'Rate hike will throw lot of people out from jobs'

Rediff.com23 May 2022

'Nobody is talking about the inequality that is going to come.'

Equity MFs Mop Up Rs 46,700 Crore

Equity MFs Mop Up Rs 46,700 Crore

Rediff.com27 Dec 2021

New fund offers collection in the current calendar year was the highest in a decade, with 13 of the 70 equity schemes cornering 75 per cent of the amount raised.

Brazil suspends Bharat Biotech's Covaxin clinical trials

Brazil suspends Bharat Biotech's Covaxin clinical trials

Rediff.com24 Jul 2021

The termination of the pact comes after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.

Omicron variant jab could be ready in 100 days: Pfizer

Omicron variant jab could be ready in 100 days: Pfizer

Rediff.com2 Dec 2021

Pfizer's chief executive Dr Albert Bourla told the BBC that he is of the view that annual vaccinations would be needed to maintain a "very high level of protection" against the deadly disease that has claimed over five million lives across the world.

'It will take time for market to recover'

'It will take time for market to recover'

Rediff.com21 Dec 2021

'The correction could take two to three months and traders need to be careful.' 'For investors, this could be a good time to nibble in.'

Winter session begins today, farm law repeal among 26 bills on agenda

Winter session begins today, farm law repeal among 26 bills on agenda

Rediff.com29 Nov 2021

The government's agenda also includes the Cryptocurrency and Regulation of Official Digital Currency Bill, 2021.

What India needs to become $5 trn economy

What India needs to become $5 trn economy

Rediff.com14 Sep 2021

India will need $8 trillion (around Rs 588 lakh crore) of gross capital formation or new greenfield assets to become a $5 trillion (around Rs 368 lakh crore) economy by FY2027, a report said. The report by Deloitte said despite the COVID-19 disruption, FDI inflow into the country provides necessary optimism and display underlying strengths of the Indian economy. In FY2020-21, FDI inflows (including equity, re-invested earnings, and capital) amounted to a record $81.72 billion, 10 per cent higher than the previous financial year, it said.